AI-Driven Biomarker Predicts Optimum Length of Treatment for Prostate Cancer

A biomarker developed with digitalized pathology and artificial intelligence demonstrated it was able to identify which men treated with radiation for high-risk localized prostate cancer could be spared long-term hormone therapy and its potential side effects.

Presenting their findings on June 4 at the American Society of Clinical Oncology meeting, Duke Cancer Institute researchers reported results from a phase 3 trial involving the National Cancer Institute Cooperative Group NRG/RTOG 9202 of the successful AI-derived digital pathology tool.

Read the press release.